

Estrogen Receptor Beta - Pipeline Review, H1 2020

<https://marketpublishers.com/r/E66181158D89EN.html>

Date: April 2020

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: E66181158D89EN

Abstracts

Estrogen Receptor Beta - Pipeline Review, H1 2020

SUMMARY

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor Beta - Pipeline Review, H1 2020, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo%li%or hetero-dimers that interact with specific DNA sequences to activate transcription.

The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 5 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Musculoskeletal Disorders, Women's Health, Genetic Disorders, Hormonal Disorders, Immunology, Male Health and Metabolic Disorders which include indications Multiple Sclerosis, Osteoporosis, Alzheimer's Disease, Breast Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Colon

Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hormone Sensitive Breast Cancer, Inflammation, Leiomyosarcoma, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic's Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer, Post Menopausal Mood Disorder, Precocious Puberty, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).

Furthermore, this report also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Atossa Therapeutics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Eli Lilly and Co

Endece LLC

EndoCeutics Inc

Helixmith Co Ltd

Huons Co Ltd

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Oasmia Pharmaceutical AB

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles

(bazedoxifene acetate + cholecalciferol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dehydrodiconiferyl alcohol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erteberel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

estradiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfestrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-3944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-9520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Loseasonique - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize ESR2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ESR2 for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate

Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology

Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer

Mar 27, 2019: Combo better for HR+ breast cancer patients

Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant

Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy

Oct 04, 2018: Mayo researchers identify potential new treatment for subset of women with triple-negative breast cancer

Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston

Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product

Dec 11, 2017: AstraZeneca's Faslodex Rejects For Use Within NHS Scotland

Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib

Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib

Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective

Appendix

Methodology

Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Atossa Therapeutics Inc, H1 2020
Pipeline by Avivia BV, H1 2020
Pipeline by Eagle Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Endece LLC, H1 2020
Pipeline by EndoCeutics Inc, H1 2020
Pipeline by Helixmith Co Ltd, H1 2020
Pipeline by Huons Co Ltd, H1 2020
Pipeline by Karo Pharma AB, H1 2020
Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
Pipeline by MEI Pharma Inc, H1 2020
Pipeline by Oasmia Pharmaceutical AB, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

AstraZeneca Plc

Atossa Therapeutics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Eli Lilly and Co

Endece LLC

EndoCeutics Inc

Helixmith Co Ltd

Huons Co Ltd

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Oasmia Pharmaceutical AB

I would like to order

Product name: Estrogen Receptor Beta - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/E66181158D89EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E66181158D89EN.html>